The order is the first from a European government following CE-IVD mark in September. The firm expects to ship 1.2 million of the assays by mid-November.
Quotient recorded a $7.5 million milestone payment in the quarter from Ortho Clinical Diagnostics as part of the companies' restructured distributor arrangement.
Quidel expects to launch at least four new products over the next year and commented on its overall COVID-19 strategy, as well as R&D plans, M&A possibilities, and other updates.
The ratio of IL-6 to IL-10 biomarkers might give clinicians insight into how severe the inflammatory response to SARS-CoV-2 could be in certain patients.
Kantaro said that authorized clinical testing laboratories in Europe can use its enzyme-linked immunoassays, which detect IgG antibodies to two coronavirus antigens.
The reissued EUA expands the types of samples that may be used with the Broad Institute's PCR-based SARS-CoV-2 test, which was first authorized in July.
Ortho said its antigen test offers 98.9 percent concordance to real-time PCR tests, making it a viable alternative for mass-scale testing during the pandemic.
Among its recommendations, the FDA said antigen tests for the coronavirus should have a minimum sensitivity of 80 percent for all sample types submitted.
FIND said the funds were awarded as part of the Access to COVID-19 (ACT) Accelerator Diagnostics Pillar to accelerate testing to help mitigate the pandemic.
The third quarter continued Abbott's streak of offsetting base business declines with COVID-19 testing, with 38 percent growth in the diagnostics business.
The company said it could produce 3 million antigen tests before the end of this year and between 15 million and 20 million tests per month starting next year.
